Shanghai Henlius Biotech

This study tests a new combination of two drugs, HLX43 and serplulimab, in 120 people with advanced lung cancer that has spread or cannot be removed by surgery. The goal is to find the best dose and see if the treatment can shrink tumors. Participants must be between 18 and 75 ye…

This study tests whether a new drug called HLX15-SC works as well as the approved drug DARZALEX FASPRO® for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 258 participants will receive either the new drug or the approved one, along with…

This early-phase study tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors, especially in ovarian and related cancers. About 41 pa…

This early-stage study tests whether a new drug called HLX18 works like the approved cancer drug OPDIVO. About 174 adults with esophageal cancer, melanoma, or bladder cancer who had surgery to remove their tumors will receive either HLX18 or OPDIVO. The main goal is to compare ho…

This early-phase study tests a new drug called HLX3902 in about 48 adults with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The drug is a special antibody designed to help the immune system attack cancer cells. The main goals…

This study tests a new drug called HLX43, alone or with other immune-boosting drugs, for people with advanced triple-negative breast cancer that has spread or come back. The goal is to see if the drug shrinks tumors and how safe it is. About 180 adults with this specific type of …

This study tests two new drugs (HLX43 alone or with HLX07) against a standard chemotherapy (docetaxel) in people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. About 671 adults will take part to see if the new options improve survival…

This study tests whether a new combination of drugs (HLX87 and HLX22) works better than the standard treatment for people with HER2-positive early or locally advanced breast cancer. About 817 participants will receive the drugs before surgery to see if the cancer completely disap…

This study tests a new drug combination (HLX43 plus HLX07 or serplulimab) in people with advanced or metastatic colorectal cancer that has stopped responding to standard first treatment. The goal is to see if the combination can shrink tumors or slow disease progression. About 12…

This early-stage study tests whether a new drug called HLX05-N works as well as the standard drug Erbitux for people with metastatic colorectal cancer that has certain genetic features. About 387 adults will receive either HLX05-N or Erbitux along with chemotherapy. The goal is t…

This study tests whether adding an experimental drug (HLX07) to standard immunotherapy and chemotherapy can better control advanced squamous non-small cell lung cancer. About 720 adults with stage 3 or 4 disease will receive either the new combination or standard treatment. The g…

This early-stage study tests a new drug called HLX97 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 138 adults with certain breast…

This study tests a new drug called HLX43 in 60 people with a common type of advanced breast cancer (HR+ HER2-) that has stopped responding to standard hormone therapy. The drug is designed to target and attack cancer cells while sparing healthy ones. The goal is to see if it can …

This study tests a new drug called HLX43 in 100 people with advanced pancreatic cancer that has not responded to other treatments. The drug targets a protein on cancer cells to help the immune system attack them. The goal is to find the best dose and see if it can shrink tumors o…

This early-stage study tests a new drug called HLX48 in 72 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. HLX48 is designed to target two cancer-related proteins, …

This early-stage study tests a new drug (HLX319) against an approved one (EU-Phesgo®) in 24 healthy Chinese men. The goal is to see how the body processes each drug and check for side effects. No treatment benefit is expected for participants.

This early-stage study tests a lab-made version of a natural enzyme called hyaluronidase in 24 healthy Chinese men aged 18 to 45. The main goal is to check for side effects, not to treat any disease. Participants receive the enzyme and are monitored for reactions, injection site …